Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma - PubMed
5 hours ago
- #mantle cell lymphoma
- #acalabrutinib
- #first-line therapy
- CARiBOU (ACCRU-LY-1804) is a phase 2 trial testing a multitargeted first-line regimen for untreated mantle cell lymphoma (MCL).
- The regimen combines alternating VR-CAP and R-cytarabine with continuous acalabrutinib over six 21-day cycles.
- Primary endpoint: complete metabolic response (CMR) rate of 90% (37/41 patients).
- Secondary outcomes: 79% achieved undetectable MRD at a 10^-6 threshold, with 18-month PFS of 79% and OS of 96%.
- Toxicities were primarily hematologic (78% grade 3 AEs), with manageable safety and no treatment-related deaths.
- The regimen is an efficient, highly effective outpatient therapy that allows MRD-guided decisions on consolidation.